Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Amphotericin B for ABPA Remission
NCT01857479Phase 3Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- May 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amphotericin b in allergic bronchopulmonary aspergillosis (ABPA), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Time to first relapse at 12 months. Started May 2013; status: completed.
02
Drugs
amphotericin b
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT01857479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857479.